IL278616A - - Google Patents
Info
- Publication number
- IL278616A IL278616A IL27861620A IL27861620A IL278616A IL 278616 A IL278616 A IL 278616A IL 27861620 A IL27861620 A IL 27861620A IL 27861620 A IL27861620 A IL 27861620A IL 278616 A IL278616 A IL 278616A
- Authority
- IL
- Israel
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669915P | 2018-05-10 | 2018-05-10 | |
| PCT/US2019/031858 WO2019217916A1 (en) | 2018-05-10 | 2019-05-10 | Methods for prognosis and management of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278616A true IL278616A (https=) | 2021-01-31 |
| IL278616B1 IL278616B1 (en) | 2024-10-01 |
| IL278616B2 IL278616B2 (en) | 2025-02-01 |
Family
ID=66655475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278616A IL278616B2 (en) | 2018-05-10 | 2019-05-10 | Methods for the prognosis and treatment management of a disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210231686A1 (https=) |
| EP (1) | EP3791188A1 (https=) |
| JP (2) | JP7371019B2 (https=) |
| KR (1) | KR20210014109A (https=) |
| CN (1) | CN112424608A (https=) |
| AU (1) | AU2019264996A1 (https=) |
| IL (1) | IL278616B2 (https=) |
| WO (1) | WO2019217916A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309046B2 (en) | 2017-04-21 | 2025-03-01 | Implicit Bioscience Ltd | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
| CN113842449B (zh) * | 2021-09-08 | 2024-02-23 | 乐卫东 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
| WO2025049671A1 (en) * | 2023-08-30 | 2025-03-06 | The Methodist Hospital | Markers of amyotrophic lateral sclerosis survival and uses thereof |
| WO2025058005A1 (ja) * | 2023-09-15 | 2025-03-20 | 国立大学法人徳島大学 | 筋萎縮性側索硬化症（ａｌｓ）と関連するバイオマーカー |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| ES2083152T3 (es) * | 1990-11-30 | 1996-04-01 | Monoclonetics Int | Metodos para el diagnostico de dolores cronicos lumbares y cervicales. |
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| CA2319828A1 (en) | 1998-01-29 | 1999-08-05 | Miller, Samuel | High density arrays for proteome analysis and methods and compositions therefor |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| AU2001255436A1 (en) | 2000-04-17 | 2001-10-30 | Transtech Pharma | Protein expression system arrays and use in biological screening |
| GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
| US20050130320A1 (en) | 2000-11-09 | 2005-06-16 | George Shaji. T. | Method for identifying the proteome of cells using an antibody library microarray |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| US6800453B2 (en) | 2001-01-23 | 2004-10-05 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
| WO2003062444A2 (en) | 2001-11-13 | 2003-07-31 | Emory University | Array systems and methods |
| JP2005510524A (ja) * | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
| AU2003224674A1 (en) | 2002-03-11 | 2003-09-29 | Hk Pharmaceuticals, Inc. | Compounds and methods for analyzing the proteome |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| ES2406266T3 (es) * | 2004-05-11 | 2013-06-06 | Mochida Pharmaceutical Co., Ltd. | Antígeno CD14 soluble novedoso |
| WO2010102412A1 (en) * | 2009-03-11 | 2010-09-16 | Augurex Life Sciences Corporation | Compositions and methods for characterizing arthritic conditions |
| BR112012002333A2 (pt) * | 2009-08-06 | 2017-07-18 | Neuraltus Pharmaceuticals Inc | método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| EP2501720A2 (en) * | 2009-11-18 | 2012-09-26 | Lascco SA | Ifn inhibitors in the treatment of motoneuron diseases |
| WO2011111043A1 (en) * | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
| WO2012004276A2 (en) * | 2010-07-06 | 2012-01-12 | Fondazione Telethon | Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits |
| US9506923B2 (en) * | 2011-08-12 | 2016-11-29 | Lsi Medience Corporation | Method of diagnosing surgical site infections |
| US10184151B2 (en) * | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| WO2014102333A1 (en) * | 2012-12-28 | 2014-07-03 | Mitsubishi Chemical Medience Corporation | Use of scd14 or its fragments or derivatives for risk stratisfaction, diagnosis and prognosis |
| EP3142674A4 (en) * | 2014-05-16 | 2018-01-17 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
| WO2016083374A1 (en) * | 2014-11-25 | 2016-06-02 | F. Hoffmann-La Roche Ag | Biomarkers of fast progression of chronic kidney disease |
| HK1250012A1 (zh) * | 2015-04-02 | 2018-11-23 | The Methodist Hospital System | 基於多孔硅微粒的癌症疫苗及增强抗肿瘤免疫的方法 |
| US10724095B2 (en) * | 2015-12-16 | 2020-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections |
| WO2017147378A1 (en) * | 2016-02-25 | 2017-08-31 | The Trustees Of Columbia University In The City Of New York | Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity |
| IL309046B2 (en) | 2017-04-21 | 2025-03-01 | Implicit Bioscience Ltd | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
| AU2024238511A1 (en) * | 2023-03-21 | 2025-10-02 | Coya Therapeutics, Inc. | Biomarkers of amyotrophic lateral sclerosis and uses thereof |
-
2019
- 2019-05-10 AU AU2019264996A patent/AU2019264996A1/en not_active Abandoned
- 2019-05-10 JP JP2020563696A patent/JP7371019B2/ja active Active
- 2019-05-10 WO PCT/US2019/031858 patent/WO2019217916A1/en not_active Ceased
- 2019-05-10 KR KR1020207034330A patent/KR20210014109A/ko not_active Ceased
- 2019-05-10 IL IL278616A patent/IL278616B2/en unknown
- 2019-05-10 EP EP19726841.0A patent/EP3791188A1/en not_active Withdrawn
- 2019-05-10 US US17/054,131 patent/US20210231686A1/en not_active Abandoned
- 2019-05-10 CN CN201980045566.7A patent/CN112424608A/zh active Pending
-
2023
- 2023-10-18 JP JP2023179310A patent/JP2023181255A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL278616B2 (en) | 2025-02-01 |
| JP2021523375A (ja) | 2021-09-02 |
| US20210231686A1 (en) | 2021-07-29 |
| JP7371019B2 (ja) | 2023-10-30 |
| IL278616B1 (en) | 2024-10-01 |
| CN112424608A (zh) | 2021-02-26 |
| EP3791188A1 (en) | 2021-03-17 |
| WO2019217916A1 (en) | 2019-11-14 |
| JP2023181255A (ja) | 2023-12-21 |
| AU2019264996A1 (en) | 2020-11-26 |
| KR20210014109A (ko) | 2021-02-08 |